Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
OXNARD, Calif., Dec. 20, 2016 -- CURE Pharmaceutical (OTC Pink:CURR), a preeminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, announces today the completion of a going public transaction and the issuance of its new stock symbol - CURR.
“After nearly six years of intense R&D activities, CURE Pharmaceutical is pleased to finally become a publicly traded entity, and anticipates a series of exciting business development announcements in the months to come,” said Rob Davidson, CEO of CURE Pharmaceutical.
Headquartered in Oxnard, CA, CURE Pharmaceutical has developed and manufactures the most advanced oral thin film (CureFilm™) on the market today supported by its in-house, industry-leading full service cGMP manufacturing facility. CureFilm is more stable and durable than other oral thin films, with the ability to augment the dissolution for the intended rate of release through the bucal or gastrointestinal system. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance, through its patented application of creating multiple layers, and sub-encapsulation of the delivered compound, potentially improving onset of action, lowering dosing, and enhancing, efficacy thereby widening the therapeutic index.
CURE Pharmaceutical is now traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Forward-looking statements
This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 [email protected]
